Research News and Research

RSS

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

31 Mar 2010

Obama signs final health changes into law

President Barack Obama signed Congress's health reconciliation bill today, making final changes to the health overhaul law. 'This day affirms our ability to overcome the challenges of our politics and meet the challenges of our time,' Obama told a college audience outside Washington, as he signed into law final changes to the sweeping plan approved by lawmakers last week, along with reforms in college student loan programs."

31 Mar 2010

Praxis extends patient recruitment services for international HCV study

Praxis, a company specializing in centralized patient recruitment for clinical research studies, is extending patient recruitment services to a top 20 pharmaceutical company for an international Hepatitis C Virus study. The study explores an investigational drug's effectiveness for this condition affecting almost 4 million Americans.

31 Mar 2010

Top neurologists to receive 2010 AAN Alliance Awards

The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.

31 Mar 2010

Insurers agree to administration view on kids' coverage

Uncertainty over whether the health overhaul would deliver promised insurance protections to children came to a quick end Monday when insurers told the administration they would not seek to block regulations clarifying the matter, The Associated Press reports. At issue is whether insurers would be required to offer plans to children with preexisting conditions right away.

31 Mar 2010

Overweight infants may experience delayed motor skills

Those cute little rolls of fat some infants have may actually slow their ability to crawl and walk, according to a new study by the University of North Carolina at Chapel Hill.

31 Mar 2010

State roundup: Romney on Mass. care, Kansas Rx costs, Colorado insurance costs

The Boston Globe, on former Mass. Gov. Mitt Romney's reaction to the new federal health law: "The former governor, who has been mentioned as a possible candidate again for president in 2012, had labeled Obama's bill 'unhealthy for America' and has called for its repeal, even as conservative critics say it was modeled on Romney's policy."

31 Mar 2010

Study indicates estrogenic drug could help treat schizophrenia

An estrogenic drug that influences neurotransmitter and neuronal systems in the brain is showing promise as an effective therapy for women who suffer from schizophrenia.

31 Mar 2010

Insurers brace for overhaul changes

The Charleston (W.Va.) Daily Mail: The health overhaul seeks to insure millions of Americans who do not currently have coverage with new subsidies, in essence, delivering millions of new customers to insurers. But, the bill would also guarantee people won't be excluded from coverage because of sickness, a potentially costly proposition for insurance firms who continue to complain that too few Americans will become insured and the risk won't be spread thinly enough to offset coverage of the sickest people.

31 Mar 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

Vision CRC scientists discover new technology to control myopia

Scientists from the Vision Cooperative Research Centre in Australia today announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners - the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

31 Mar 2010

Close-ups on how the health overhaul gives and takes away

"An association representing 300 large corporations urged President Obama and Congress on Monday to repeal a provision of the health care overhaul that prompted AT&T, Caterpillar and other companies to announce substantial charges for the current quarter."

31 Mar 2010

Asclera injection receives FDA approval

The U.S. Food and Drug Administration today approved Asclera (polidocanol) injection for the treatment of small types of abnormally swollen or twisted veins called varicose veins.

31 Mar 2010

Facts and treatment options for endometriosis

One out of every two women struggling to conceive may suffer from endometriosis - the leading cause of infertility - according to research from Camran Nezhat, M.D., gynecologist at El Camino Hospital, the hospital of the Silicon Valley.

31 Mar 2010

States mull joining health care reform lawsuits or keeping out of it

The Associated Press/New York Times: Indiana has joined the lawsuit brought by 13 states challenging the constitutionality of a mandate on Americans to carry health insurance in the new health reform law. "State Attorney General Greg Zoeller said Monday that Indiana would be added to an amended version of the lawsuit against the law that is expected to be filed soon" (3/29).

31 Mar 2010

Women, diabetics, dementia patients most likely to fall in 'doughnut hole'; Reform seeks to close coverage gap

Among elderly Americans, women and those with diabetes and dementia are most likely to find themselves in the Medicare Part D drug plan 'doughnut hole,' the coverage gap that occurs after a beneficiary has reached the annual coverage limit but hasn't spent enough on drugs to qualify for catastrophic coverage.

31 Mar 2010

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

ACCESS PHARMACEUTICALS, INC. signed a collaborative development agreement with bioRASI, LLC, a full-service global CRO specializing in the accelerated development of novel therapeutics, to facilitate clinical development for its Cobalamin™-based oral insulin and other Cobalamin-based products.

31 Mar 2010

Despite simmering GOP rage on health bill, some Republicans say they can still work with Democrats

NPR reports: "Though conservative anger with Washington over the newly signed bill has been particularly hot, some longtime political observers see a revival of previous populist movements from the right. ... Chip Berlet with Political Research Associates, a liberal group that tracks populist anti-government movements, says this is nothing new.

31 Mar 2010

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).

31 Mar 2010

Hospira acquires Orchid's injectables formulations business

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has completed the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million.

31 Mar 2010